Viela Bio (Viela Bio) Gross Profit : $9.61 Mil (TTM As of Dec. 2020)

View and export this data going back to 2019. Start your Free Trial

What is Viela Bio Gross Profit?

Viela Bio's gross profit for the three months ended in Dec. 2020 was $7.95 Mil. Viela Bio's gross profit for the trailing twelve months (TTM) ended in Dec. 2020 was $9.61 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Viela Bio's gross profit for the three months ended in Dec. 2020 was $7.95 Mil. Viela Bio's Revenue for the three months ended in Dec. 2020 was $9.34 Mil. Therefore, Viela Bio's Gross Margin % for the quarter that ended in Dec. 2020 was 85.11%.

Viela Bio had a gross margin of 85.11% for the quarter that ended in Dec. 2020 => Durable competitive advantage

During the past 3 years, the highest Gross Margin % of Viela Bio was 82.49%. The lowest was 82.49%. And the median was 82.49%.

Viela Bio Gross Profit Historical Data

The historical data trend for Viela Bio's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viela Bio Gross Profit Chart

Viela Bio Annual Data

Trend

Dec18

Dec19

Dec20

Gross Profit

50.00

9.61

Viela Bio Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Gross Profit	Get a 7-Day Free Trial					30.00	-	-	1.67	7.95

Competitive Comparison of Viela Bio's Gross Profit

For the Biotechnology subindustry, Viela Bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viela Bio's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viela Bio's Gross Profit distribution charts can be found below:

* The bar in red indicates where Viela Bio's Gross Profit falls into.

Viela Bio Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Viela Bio's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as

Gross Profit (A: Dec. 2020 )	=	Revenue	-	Cost of Goods Sold
	=	11.652	-	2.04
	=	9.61

Viela Bio's Gross Profit for the quarter that ended in Dec. 2020 is calculated as

Gross Profit (Q: Dec. 2020 )	=	Revenue	-	Cost of Goods Sold
	=	9.336	-	1.39
	=	7.95

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.61 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Viela Bio's Gross Margin % for the quarter that ended in Dec. 2020 is calculated as

Gross Margin % (Q: Dec. 2020 )	=	Gross Profit (Q: Dec. 2020 )	/	Revenue (Q: Dec. 2020 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	7.95	/	9.336
	=	85.11 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Viela Bio (NAS:VIE) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Viela Bio had a gross margin of 85.11% for the quarter that ended in Dec. 2020 => Durable competitive advantage

Viela Bio Gross Profit Related Terms

Thank you for viewing the detailed overview of Viela Bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

Viela Bio (Viela Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viela Bio Inc (NAS:VIE) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

N/A

Address

One MedImmune Way, First Floor, Area Two, Gaithersburg, MD, USA, 20878

Website

https://www.vielabio.com

Viela Bio Inc is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.

Executives

Chris Nolet	director	C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Rachelle Suzanne Jacques	director	C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE, NORWOOD MA 02062
Edward Hu	director	10975 TORREY PINES ROAD, LA JOLLA CA 92037
Boyu Capital General Partner Iii, L.p.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital General Partner Iii, Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Group Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xyxy Holdings Ltd.	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Investment Management Ltd	10 percent owner	SUITE 1501, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boundless Meadow Ltd	10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Xiaomeng Tong	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Yanling Cao	director, 10 percent owner	SUITE 1518, TWO PACIFIC PLACE 88 QUEENSWAY HONG KONG K3 00000
Boyu Capital Fund Iii, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED BOX 309, UGLAND HOUSE GRAND CAYMAN E9 KYL-1104
Boyu Capital Opportunities Master Fund	10 percent owner	CAYMAN CORPORATE CENTRE 27 HOSPITAL ROAD, GEORGE TOWN CAYMAN ISLANDS E9 KY1-9008
Zhengbin Yao	director, officer: Chief Executive Officer	10301 STELLA LINK ROAD, HOUSTON TX 77025
William Ragatz	officer: VP, Head of Commercial	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878